Open Questions: Biomarkers

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Biomarkers'
open ⚖ 1500
Population screening:
📑 0.50 💥 0.50
open ⚖ 1500
p-tau217 + p-tau181
📑 0.50 💥 0.50
open ⚖ 1500
FDA-cleared alpha-synuclein SAA:
📑 0.50 💥 0.50
open ⚖ 1500
Improved blood SAA sensitivity:
📑 0.50 💥 0.50
open ⚖ 1500
Automated platforms:
📑 0.50 💥 0.50
open ⚖ 1500
Strain characterization:
📑 0.50 💥 0.50
open ⚖ 1500
Combination with genetic risk scores:
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care
📑 0.50 💥 0.50
open ⚖ 1500
Multi- analyte
📑 0.50 💥 0.50
open ⚖ 1500
Clinical implementation
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic studies
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic development
📑 0.50 💥 0.50
open ⚖ 1500
Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Accessibility
📑 0.50 💥 0.50
open ⚖ 1500
Integration
📑 0.50 💥 0.50
open ⚖ 1500
Ultra-high field (7T)
📑 0.50 💥 0.50
open ⚖ 1500
Real-time fMRI
📑 0.50 💥 0.50
open ⚖ 1500
Multimodal integration
📑 0.50 💥 0.50
open ⚖ 1500
Can harmful inflammation be selectively modulated?
📑 0.50 💥 0.50
open ⚖ 1500
Multiplexed panels:
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care development:
📑 0.50 💥 0.50
open ⚖ 1500
Treatment response monitoring:
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting of seeds:
📑 0.50 💥 0.50
open ⚖ 1500
Portable olfactometers
📑 0.50 💥 0.50
open ⚖ 1500
Electroolfactogram
📑 0.50 💥 0.50
open ⚖ 1500
Olfactory nanoparticle detection
📑 0.50 💥 0.50
open ⚖ 1500
AI-integrated analysis
📑 0.50 💥 0.50
open ⚖ 1500
Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Prospective longitudinal
📑 0.50 💥 0.50
open ⚖ 1500
Multi-center
📑 0.50 💥 0.50
open ⚖ 1500
Trial enrichment
📑 0.50 💥 0.50
open ⚖ 1500
Pharmacodynamic
📑 0.50 💥 0.50
open ⚖ 1500
Patient stratification
📑 0.50 💥 0.50
open ⚖ 1500
Blood-based assays
📑 0.50 💥 0.50
open ⚖ 1500
Automated systems
📑 0.50 💥 0.50
open ⚖ 1500
Multiplexing
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care
📑 0.50 💥 0.50
open ⚖ 1500
Digital ELISA
📑 0.50 💥 0.50
open ⚖ 1500
Strain characterization
📑 0.50 💥 0.50
open ⚖ 1500
Progression markers
📑 0.50 💥 0.50
open ⚖ 1500
Treatment monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Population screening
📑 0.50 💥 0.50
open ⚖ 1500
Biological understanding
📑 0.50 💥 0.50
open ⚖ 1500
Predictive modeling
📑 0.50 💥 0.50
open ⚖ 1500
International collaboration
📑 0.50 💥 0.50
open ⚖ 1500
Large-scale validation studies
📑 0.50 💥 0.50
open ⚖ 1500
Correlation with prodromal markers
📑 0.50 💥 0.50
open ⚖ 1500
Comparison across synucleinopathies
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal studies
📑 0.50 💥 0.50
open ⚖ 1500
Lateral flow assays
📑 0.50 💥 0.50
open ⚖ 1500
Integrated devices
📑 0.50 💥 0.50
open ⚖ 1500
Home testing
📑 0.50 💥 0.50
open ⚖ 1500
Reference materials
📑 0.50 💥 0.50
open ⚖ 1500
Harmonization
📑 0.50 💥 0.50
open ⚖ 1500
Quality certification
📑 0.50 💥 0.50
open ⚖ 1500
P-tau isoforms
📑 0.50 💥 0.50
open ⚖ 1500
Proteomic panels
📑 0.50 💥 0.50
open ⚖ 1500
Multi-modal integration
📑 0.50 💥 0.50
open ⚖ 1500
LRRK2 inhibitor approval:
📑 0.50 💥 0.50
open ⚖ 1500
GBA chaperone pivotal trials:
📑 0.50 💥 0.50
open ⚖ 1500
APOE-guided anti-amyloid therapy protocols:
📑 0.50 💥 0.50
open ⚖ 1500
Multi-ancestry PRS:
📑 0.50 💥 0.50
open ⚖ 1500
SAA-guided genetic testing:
📑 0.50 💥 0.50
open ⚖ 1500
Combination genetic + biomarker risk scores:
📑 0.50 💥 0.50
open ⚖ 1500
Gene editing for monogenic cases:
📑 0.50 💥 0.50
open ⚖ 1500
Preventive intervention based on genetic risk:
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism-matched clinical trials:
📑 0.50 💥 0.50
open ⚖ 1500
Population screening:
📑 0.50 💥 0.50
open ⚖ 1500
Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
p-tau217 + GFAP
📑 0.50 💥 0.50
open ⚖ 1500
p-tau217 + NfL
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning
📑 0.50 💥 0.50
open ⚖ 1500
Clinical translation
📑 0.50 💥 0.50
open ⚖ 1500
What drives the microglial state transition?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetics affect microglial biomarker patterns?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal timing for immunomodulatory intervention?
📑 0.50 💥 0.50
open ⚖ 1500
How does vimentin contribute to glial scar formation vs. beneficial astrogliosis?
📑 0.50 💥 0.50
open ⚖ 1500
Can vimentin be safely targeted without affecting normal CNS function?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the switch from protective to detrimental vimentin expression?
📑 0.50 💥 0.50
open ⚖ 1500
How do post-translational modifications alter vimentin's role in disease?
📑 0.50 💥 0.50
open ⚖ 1500
Multiplex immunoassays
📑 0.50 💥 0.50
open ⚖ 1500
Single-molecule array (Simoa)
📑 0.50 💥 0.50
open ⚖ 1500
Mass spectrometry
📑 0.50 💥 0.50
open ⚖ 1500
Combination panels
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
Exosomal markers
📑 0.50 💥 0.50
open ⚖ 1500
Phospho-tau isoforms
📑 0.50 💥 0.50
open ⚖ 1500
Synaptic proteins
📑 0.50 💥 0.50
open ⚖ 1500
Multi-omics integration
📑 0.50 💥 0.50
open ⚖ 1500
Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care testing
📑 0.50 💥 0.50
open ⚖ 1500
Combination biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Trial endpoints
📑 0.50 💥 0.50
open ⚖ 1500
Assay development
📑 0.50 💥 0.50
open ⚖ 1500
Clinical trials
📑 0.50 💥 0.50
open ⚖ 1500
Multi-parametric ASL
📑 0.50 💥 0.50
open ⚖ 1500
Guideline development
📑 0.50 💥 0.50
open ⚖ 1500
Other neurodegenerative diseases
📑 0.50 💥 0.50
open ⚖ 1500
Aging research
📑 0.50 💥 0.50
open ⚖ 1500
Brain injury
📑 0.50 💥 0.50
open ⚖ 1500
Psychiatric disorders
📑 0.50 💥 0.50
open ⚖ 1500
Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care
📑 0.50 💥 0.50
open ⚖ 1500
Multi-modal integration
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal studies
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning integration
📑 0.50 💥 0.50
open ⚖ 1500
Continuous monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Multimodal combinations
📑 0.50 💥 0.50
open ⚖ 1500
AI-powered analysis
📑 0.50 💥 0.50
open ⚖ 1500
3D spiral readout
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning integration
📑 0.50 💥 0.50
open ⚖ 1500
Cross-site harmonization
📑 0.50 💥 0.50
open ⚖ 1500
Clinical integration
📑 0.50 💥 0.50
open ⚖ 1500
Dynamic ASL
📑 0.50 💥 0.50
open ⚖ 1500
Multiband ASL
📑 0.50 💥 0.50
open ⚖ 1500
AI-powered analysis:
📑 0.50 💥 0.50
open ⚖ 1500
Voice biomarkers:
📑 0.50 💥 0.50
open ⚖ 1500
Passive monitoring:
📑 0.50 💥 0.50
open ⚖ 1500
Multimodal integration:
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care devices:
📑 0.50 💥 0.50
open ⚖ 1500
Multiplexed panels:
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning:
📑 0.50 💥 0.50
open ⚖ 1500
Home monitoring:
📑 0.50 💥 0.50
open ⚖ 1500
Synaptic vesicle glycoproteins
📑 0.50 💥 0.50
open ⚖ 1500
Activity-regulated cytoskeleton-associated protein (Arc)
📑 0.50 💥 0.50
open ⚖ 1500
Synuclein oligomers
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning
📑 0.50 💥 0.50
open ⚖ 1500
Quantitative norms
📑 0.50 💥 0.50
open ⚖ 1500
Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Clinical implementation
📑 0.50 💥 0.50
open ⚖ 1500
Disease-Specific Phosphorylation
📑 0.50 💥 0.50
open ⚖ 1500
Soluble Species Marker
📑 0.50 💥 0.50
open ⚖ 1500
Amyloid Dependency
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal Tracking
📑 0.50 💥 0.50
open ⚖ 1500
Centrifugation
📑 0.50 💥 0.50
open ⚖ 1500
Freeze-Thaw
📑 0.50 💥 0.50
open ⚖ 1500
Multimodal panels
📑 0.50 💥 0.50
open ⚖ 1500
Blood-based assays
📑 0.50 💥 0.50
open ⚖ 1500
Cell-specific markers
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal tracking
📑 0.50 💥 0.50
open ⚖ 1500
PET GABA_A receptor imaging
📑 0.50 💥 0.50
open ⚖ 1500
MRS GABA measurement
📑 0.50 💥 0.50
open ⚖ 1500
Blood-based detection
📑 0.50 💥 0.50
open ⚖ 1500
Multi-analyte panels
📑 0.50 💥 0.50
open ⚖ 1500
Assay standardization
📑 0.50 💥 0.50
open ⚖ 1500
Clinical validation
📑 0.50 💥 0.50
open ⚖ 1500
Current role
📑 0.50 💥 0.50
open ⚖ 1500
Future potential
📑 0.50 💥 0.50
open ⚖ 1500
Combination approach
📑 0.50 💥 0.50
open ⚖ 1500
Specialty referral
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarker integration:
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning models:
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care testing:
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine:
📑 0.50 💥 0.50
open ⚖ 1500
Mass spectrometry
📑 0.50 💥 0.50
open ⚖ 1500
Clinical Trials
📑 0.50 💥 0.50
open ⚖ 1500
Assay Development
📑 0.50 💥 0.50
open ⚖ 1500
Combination Biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic Studies
📑 0.50 💥 0.50
open ⚖ 1500
Multi-analyte
📑 0.50 💥 0.50
open ⚖ 1500
Blood-based development
📑 0.50 💥 0.50
open ⚖ 1500
AI integration:
📑 0.50 💥 0.50
open ⚖ 1500
Continuous fluid monitoring:
📑 0.50 💥 0.50
open ⚖ 1500
Smartphone-as-lab:
📑 0.50 💥 0.50
open ⚖ 1500
Digital twin:
📑 0.50 💥 0.50
open ⚖ 1500
Multi-omics integration:
📑 0.50 💥 0.50
open ⚖ 1500
Machine learning:
📑 0.50 💥 0.50
open ⚖ 1500
Dynamic risk:
📑 0.50 💥 0.50
open ⚖ 1500
Treatment selection:
📑 0.50 💥 0.50
open ⚖ 1500
Cognitive progression
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker trajectory
📑 0.50 💥 0.50
open ⚖ 1500
Treatment response
📑 0.50 💥 0.50
open ⚖ 1500
Automation:
📑 0.50 💥 0.50
open ⚖ 1500
Standardized biomarker data
📑 0.50 💥 0.50
open ⚖ 1500
Cross-cohort harmonization
📑 0.50 💥 0.50
open ⚖ 1500
Open Science
📑 0.50 💥 0.50
open ⚖ 1500
Multi-analyte panel
📑 0.50 💥 0.50
open ⚖ 1500
Asian population
📑 0.50 💥 0.50
open ⚖ 1500
Novel fluid biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Multiplex assays:
📑 0.50 💥 0.50
open ⚖ 1500
Digital quantification:
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care:
📑 0.50 💥 0.50
open ⚖ 1500
Standardization:
📑 0.50 💥 0.50
open ⚖ 1500
Clinical trials:
📑 0.50 💥 0.50
open ⚖ 1500
Companion diagnostics:
📑 0.50 💥 0.50
open ⚖ 1500
Screening programs:
📑 0.50 💥 0.50
open ⚖ 1500
Simoa Technology
📑 0.50 💥 0.50
open ⚖ 1500
Mass Spectrometry
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-Care
📑 0.50 💥 0.50
open ⚖ 1500
Core AD Panel
📑 0.50 💥 0.50
open ⚖ 1500
Neurodegeneration Panel
📑 0.50 💥 0.50
open ⚖ 1500
Multi-analyte panels
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care testing
📑 0.50 💥 0.50
open ⚖ 1500
BDNF:Neurotrophin-3 ratio
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarker correlation
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Biomarkers through bridging wiki connections. See all cross-field connections →

Cross-pollination from Researchers 697 bridges →
Cross-pollination from Technologies 1,127 bridges →
Cross-pollination from Institutions 1,258 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map